Spire Wealth Management Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Spire Wealth Management increased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 31,079 shares of the company’s stock after purchasing an additional 2,200 shares during the quarter. Spire Wealth Management’s holdings in Eli Lilly and Company were worth $19,535,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company in the 3rd quarter valued at about $36,000. Family CFO Inc acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $40,000. Finally, O Brien Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 2.8 %

Shares of LLY traded down $20.94 during midday trading on Friday, reaching $734.97. 4,595,138 shares of the company were exchanged, compared to its average volume of 2,629,045. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The stock has a 50-day moving average price of $761.06 and a 200-day moving average price of $672.28. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The company has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.62 earnings per share. Research analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LLY. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.